Physician profile
Robert David Todd
NPI 1811044621
$1,183.00
in general payments reported to CMS, 2019-2025
12 companies · $525 in 2025
The $525 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.57 · 2023: $76.15 · 2024: $566 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $447.92 | 2023-2025 | Proclaim, Eterna, Octrode |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.28 | 2024-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $118.34 | 2024-2025 | Belbuca, Xtampza |
| Curonix LLC | $111.81 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $70.55 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $68.69 | 2024-2025 | |
| Abbvie INC. | $23.22 | 2024 | |
| Nevro Corp. | $21.94 | 2024 | Senza |
| Relievant Medsystems, INC. | $15.57 | 2021 | |
| Protega Pharmaceutials INC | $15.56 | 2025 | Roxybond |
| Hikma Pharmaceuticals USA | $14.85 | 2024 | Kloxxado |
| Pfizer INC. | $13.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.